Decheng Capital Management III (Cayman)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Decheng Capital Management III (Cayman)’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-150,000	Closed	-$16.1M	–	29
2023 Q1	$16.1M	Sell	150,000 -100,000	-40%	-$11.5M	6.49%	7
2022 Q4	$27.5M	Hold	250,000	–	–	10.29%	3
2022 Q3	$14.8M	Hold	250,000	–	–	5.35%	6
2022 Q2	$7.06M	Hold	250,000	–	–	2.68%	11
2022 Q1	$9.44M	Buy	+250,000	New	+$9.88M	2.89%	12

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Decheng Capital Management III (Cayman)'s RXDX Position: Q2 2023 in Review

Decheng Capital Management III (Cayman) sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 150,000 shares — an estimated $16.1M sold.

Decheng Capital Management III (Cayman) first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $27.5M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Decheng Capital Management III (Cayman) reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Decheng Capital Management III (Cayman) sold 150,000 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $16.1M.
Decheng Capital Management III (Cayman) first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Decheng Capital Management III (Cayman)'s Prometheus Biosciences, Inc. Common Stock position peaked at $27.5M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q2 2023, filed 28 Jul 2023.